← Back to patent-cliff list
Palacaparib
Tier C — Watch / tradePalacaparib
AstraZeneca
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：PARP1
Indications (approved)：Prostate cancer, Solid tumour
Regional status
US
Phase II
2022-06-24
EU
Phase II
2022-06-24
China
Phase II
2025-10-01
Japan
Phase II
2025-10-01
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Palacaparib?
Approved indications include: Prostate cancer, Solid tumour.
When does the Palacaparib patent expire?
No public expiry year is available for Palacaparib yet; this page updates once verified.
How do I get a quote for Palacaparib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-05